Latest Conference Articles

May 5th 2022, 4:16pm

ESMO Breast Cancer Virtual Meeting

The addition of ribociclib to fulvestrant continued to significantly prolong overall survival, delayed time to second disease progression, and improved chemotherapy-free survival vs placebo plus fulvestrant in the first-line treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer.

May 2nd 2022, 7:00pm

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

May 2nd 2022, 6:00pm

The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)

April 27th 2022, 6:47pm

The combination of JSP191, fludarabine, and low-dose total body irradiation demonstrated facilitation of full donor myeloid chimerism, clearance of minimal residual disease, and a tolerable safety profile in patients with myelodysplastic syndrome or acute myeloid leukemia.

April 27th 2022, 4:46pm

Transplantation and Cellular Therapy Meetings

Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population

April 26th 2022, 4:58pm

Transplantation and Cellular Therapy Meetings

Patients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared with those who underwent haploidentical stem cell transplant.

April 26th 2022, 3:43pm

The use of 131-iodine generated high rates of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia who did not achieve a complete response following standard therapy.

April 25th 2022, 8:23pm

Transplantation and Cellular Therapy Meetings

Itolizumab decreased levels of cell surface CD6 and increased soluble CD6 in serum in patients with acute graft-vs-host-disease.

April 25th 2022, 7:28pm

Transplantation and Cellular Therapy Meetings

The use of ruxolitinib following an allogeneic hematopoietic cell transplantation was associated with the prevention of serious graft-versus-host disease.

April 25th 2022, 6:25pm

Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.

April 25th 2022, 6:05pm

Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.

April 25th 2022, 6:00pm

Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.

April 25th 2022, 5:27pm

Transplantation and Cellular Therapy Meetings

Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.

April 25th 2022, 5:00pm

The CAR T-cell therapies axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel evoked responses without increased risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome in patients with primary or secondary central nervous system large B-cell lymphoma.

April 25th 2022, 2:27pm

Transplantation and Cellular Therapy Meetings

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

April 25th 2022, 2:00pm

Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.

April 24th 2022, 11:01pm

Transplantation and Cellular Therapy Meetings

The CAR T-cell therapy axicabtagene ciloleucel produced encouraging responses when used in the first-line treatment of patients with high-risk large B-cell lymphoma.

April 24th 2022, 9:15pm

Transplantation and Cellular Therapy Meetings

The utilization of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphomas produced durable outcomes at a 2 years follow-up.

April 24th 2022, 7:58pm

Transplantation and Cellular Therapy Meetings

Belimumab could be a potential treatment used to prevent chronic graft-vs-host-disease in patients undergoing allogeneic hematopoietic transplantation by inhibiting BAFF and limiting the survival of aforeactive B cells.

April 24th 2022, 3:37pm

Transplantation and Cellular Therapy Meetings

Axicabtagene ciloleucel resulted in a longer overall survival benefit in patients with relapsed or refractory large B-cell lymphoma who did not have event-free survival events at months 12 and 24 vs those who experienced events at these time points.